Thus,selective inhibition of TREK-1/2 was shown, for the first time, tobe efficacious in the NOR paradigm and suggests therapeutic relevancefor TREK-1 and or TREK-1/2 inhibition to treat cognitive disorders. The gene discussed is KCNK2; the disease is Cognitive impairment.